Showing 4201-4210 of 9729 results for "".
- New Publication Supports Diagnostic Value of DermTech's PLAhttps://practicaldermatology.com/news/new-publication-supports-diagnostic-value-of-dermtechs-pla/2460914/Evaluation of genomic atypia with DermTech’s Pigmented Lesion Assay (PLA) increases both the real-world negative predictive value (NPV) and positive predictive value (PPV) of the melanoma diagnostic pathway and reduces biopsy burden, relative to the current visual assessment and histopathol
- AbbVie, BTL Settle Patent Disputehttps://practicaldermatology.com/news/abbvie-btl-settle-patent-dispute/2460906/BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the terms of the settlement agreement, AbbVie will pay BTL an undisclosed payment. The details of the agreement are confidential and will not be disc
- Study: UV Exposure Produces Epigenetic Changes in the Epidermis to Induce Skin Pigmentationhttps://practicaldermatology.com/news/study-uv-exposure-produces-epigenetic-changes-in-the-epidermis-to-induce-skin-pigmentation/2460905/Exposure to the sun's ultraviolet (UV) rays produces epigenetic changes in the epidermis to induce skin pigmentation, a new study shows. UV exposure causes DNA damage in epidermal cells and is a leading cause of skin cancers. To protect from the damaging effects of UV exposure, epid
- European Commission Approves UCB's BIMZELX for Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/european-commission-approves-ucbs-bimzelx-for-adults-with-moderate-to-severe-plaque-psoriasis/2460895/The European Commission (EC) has granted marketing authorization for UCB's bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab is the first approved treatment in the European Union (EU) for moderate
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- New Gel Shows Promise Against BCChttps://practicaldermatology.com/news/new-gel-shows-promise-against-bcc/2460890/Medivir AB’s topical histone deacetylase (HDAC) inhibitor remetinostat performed well in a phase II study in basal cell carcinoma (BCC), according to research published online in Clinical Cancer Research. The new gel could reduce the need for surgical
- New Survey: Americans Have Missed Out on Dating, Parties, School And Work Because of Acnehttps://practicaldermatology.com/news/new-survey-americans-have-missed-out-on-dating-parties-school-and-work-because-of-acne/2460889/Americans missed out on dating, school and hanging out with friends because of acne during the past year, according to a new survey by University Medical, the manufacturer of the Acne Wipeout skincare system. After more than a year of looking at themselves on screens and hiding behind s
- MoonLake Immunotherapeutics Taps Former Kymab CEO Simon Sturge as Chairman and Spike Loy for the Board of Directorshttps://practicaldermatology.com/news/moonlake-immunotherapeutics-taps-former-kymab-ceo-simon-sturge-as-chairman-and-spike-loy-for-the-board-of-directors/2460887/Simon Sturge is the new Chairman of MoonLake Immunotherapeutics AG, and Spike Loy has joined the Company’s Board of Directors. Mr. Sturge has 40 years of international leadership experience in the biotechnology and pharmaceutical industry. Most recently, he was Chief Ex
- Vivacare Calls on Derms to Share Knowledge During Psoriasis Awareness Monthhttps://practicaldermatology.com/news/vivacare-calls-on-terms-to-share-knowledge-during-national-psoriasis-month/2460885/Dermatologists from around the country have contributed tips to Vivacare’s education resources and Physician Directory, and the company is inviting others to join in. In honor of Psoriasis Awareness Month, Vivacare is requesting dermatologists share insights regarding psoriasis and its trea
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a